Results 61 to 70 of about 1,819,904 (233)

Drug eluting stents in 2005 [PDF]

Heart, 2005
In the last 3–5 years there has been a major shift in the management of symptomatic, obstructive coronary artery disease, with a move from predominantly surgical to increasingly a percutaneous approach. The perceived benefits of percutaneous coronary intervention (PCI) include patient convenience, ease of service expansion, and the fact that more ...
openaire   +2 more sources

Drug-eluting balloon in the treatment of a recurrent in-stent restenosis of drug-eluting stent [PDF]

Orvosi Hetilap, 2010
A koszorúér-betegség alapját jelentő atheroscleroticus folyamatok gyógyszeres kezelése mellett a percutan intervenciós módszer szerepe az utóbbi évtizedekben egyre jelentősebb. A stentek elterjedésével a percutan koszorúér-intervenció akut sikerrátája jelentős javulást mutatott, azonban a hagyományos fémstentekben keletkezett instentrestenosis újabb ...
Béla, Merkely, Zoltán, Jambrik
openaire   +2 more sources

Evaluation of Treatment Response of Calcified Nodules and Nodular Calcified Lesions Using Mean Density on Coronary Computed Tomography Angiography

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Calcified nodules (CN) and nodular calcifications (NC) present significant challenges during percutaneous coronary intervention (PCI) because of their protruding morphology and high rigidity, which often result in inadequate stent expansion and suboptimal procedural outcomes.
Akito Setoguchi, Keita Iyama, Ryosuke Iwasaki, Saburo Kusumoto, Yoshiyuki Doi, Tatsuya Nunohiro, Masayoshi Takeno, Koji Maemura   +7 more
wiley   +1 more source

Thrombosis prevention in percutaneous coronary interventions

Кардиоваскулярная терапия и профилактика, 2009
The introduction of drug-eluting stents has been a major achievement of interventional cardiology. These stents  demonstrate good clinical effectiveness and safety profile.
V. P. Lupanov, A. N. Samko
doaj  

Patient-tailored stent: Are we there yet?

Cardiology Journal
Percutaneous coronary intervention (PCI) has become a routine revascularization strategy. Percutaneous coronary intervention outcome is affected by patient- and procedure-related factors.
Piotr Arski, Jakub M. Zimodro, Magda Mucha, Paweł Jańczak, Arkadiusz Pietrasik, Aleksandra Gąsecka   +5 more
doaj   +1 more source

Coronary Perforation During Excimer Laser Angioplasty in a Patient With Prior Thoracic Radiotherapy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Management of heavily calcified coronary lesions remains challenging despite advances in plaque‐modifying technologies. Excimer laser coronary angioplasty (ELCA) is an effective adjunctive strategy with a low risk of no‐reflow. Case Summary A 75‐year‐old woman with non–ST‐segment elevation acute coronary syndrome and severe left ...
Francesco Maria Sparasci, Alessandro Cafaro, Dionigi Fischetti, Alessandro Mandurino‐Mirizzi   +3 more
wiley   +1 more source

Current status of drug-eluting stents

, 2011
First-generation drug-eluting stents (DES) with controlled release of sirolimus or paclitaxel from durable polymers compared with bare-metal stents have been consistently shown to reduce the risk of repeat revascularization procedures due to restenosis ...
Windecker, Stephan, Räber, Lorenz
core   +1 more source

Zotarolimus-eluting stent fracture at initial implantation diagnosed with StentBoost

SAGE Open Medical Case Reports, 2016
Stent fracture is a rare complication of drug-eluting stent implantation with a reported rate of 0.84%–3.2% in various clinical studies with first-generation drug-eluting stents and 29% in autopsy studies.
Alev Arat Ozkan, Umit Yasar Sinan, Aziz T Gurmen   +2 more
doaj   +1 more source

Final 2‐Year Results of the REFORM Study: A Randomized Trial of Biolimus DCB Versus Paclitaxel DCB for In‐Stent Restenosis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In the REFORM trial, treatment of coronary in‐stent restenosis with a Biolimus A9™ drug‐coated balloon (BCB) was found to be inferior with respect to in‐segment percentage stenosis at 6‐months in comparison to treatment with a standard paclitaxel coated paclitaxel‐coated balloon (PCB). Aims In this manuscript, the final prespecified
Daniel O'Callaghan, J. J. Coughlan, Fernando Alfonso, Joo‐Yong Hahn, Manel Sabate, Ralph Toelg, Samuel Copt, Sean Fitzgerald, Marie‐Claude Morice, Jasper Trevelyan, Darren Mylotte, Antonio Fernandez Ortiz, Rory Durand, Jochen Wöhrle, Franz Xever Kleber, Giuilo Stefanini, Himanshu Rai, Peter O'Kane, Robert A. Byrne   +18 more
wiley   +1 more source

Long-term effectiveness and safety of sirolimus drug-eluting stents

Medical Devices: Evidence and Research, 2011
Mahesh Bikkina, Jayanth KoneruSt Joseph Regional Medical Center, Paterson, Seton Hall University, NJ, USAAbstract: The root cause of coronary artery disease is atherosclerosis, ie, intraluminal narrowing (stenosis) of the arteries that supply blood to ...
Bikkina M, Koneru J
doaj